A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy
Status:
Active, not recruiting
Trial end date:
2025-03-05
Target enrollment:
Participant gender:
Summary
This Phase IIb study is a two part, multicenter study to evaluate the efficacy, safety,
pharmacokinetics and pharmacodynamics of ATL1102 in non-ambulant boys with Duchenne Muscular
Dystrophy aged 10 to <18 years old. The study includes a randomised, double-blind,
placebo-controlled treatment period (Part A), followed by an open labelled treatment period
(Part B).